RT Journal Article
SR Electronic
T1 Baseline drug treatments and long-term outcomes in COVID-19-hospitalized patients: results of the 2020 AUTCOV study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.22.24312424
DO 10.1101/2024.08.22.24312424
A1 Graf, Alexandra Christine
A1 Reichardt, Berthold
A1 Wagenlechner, Christine
A1 Krotka, Pavla
A1 Traxler-Weidenauer, Denise
A1 Mildner, Michael
A1 Mascherbauer, Julia
A1 Aigner, Clemens
A1 Auer, Johann
A1 Wendt, Ralph
A1 Ankersmit, Hendrik Jan
YR 2024
UL http://medrxiv.org/content/early/2024/08/22/2024.08.22.24312424.abstract
AB Limited data are available on long-term morbidity and mortality after COVID-19 hospitalization. In this population-based study, we investigated the long-term mortality and morbidity after COVID-19 hospitalization and associations with baseline drug treatments. Data were provided on hospitalized COVID-19 patients in 2020 and matched controls by the Austrian Health Insurance Funds. The primary outcome was all-cause mortality. Secondary outcomes were all-cause mortality conditional on COVID-hospital survival and re-hospitalization due to any reason. The median follow-up was 600 days. 22 571 patients aged >18 years were hospitalized in Austria in 2020 due to COVID-19. The risk of all-cause mortality was significantly higher with polypharmacy. With the exception of the youngest age group (19-40 years), antiepileptics, antipsychotics and the medicament group of iron supplements, erythropoietic stimulating agents, Vitamin B12, and folic acid were significantly associated with a higher risk of death (all p<0,001). For Non-steroidal anti-inflammatory drugs and other anti-inflammatory drugs, significantly increased survival was observed (all p<0,001). Patients had a higher drug prescription load than the control population. Long-term mortality and the risk of re-hospitalization due to any reason were also significantly greater in the patients. Antipsychotics are assumed to be an underrecognized medication group linked to worse outcomes after COVID-19 hospitalization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by the working group ARGE Ankersmit, Laboratory for Cardiac and Thoracic Diagnosis and Regeneration at the Department of Thoracic Surgery at the Medical University of Vienna.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective, national population-based study and was approved by the ethics committee of Lower Austria, Austria (Number: GS1-EK-4/747-2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes